1-StartSlider_600x1920
Commercial Stage
Biosimilar Developer
Biosimilar Developer
As a globally operating, independent biosimilar developer, Formycon actively contributes to improving patients' access to high-quality, safe and affordable biologic medicines.
1-StartSlider_600x1920
At home in the
growth market of biosimilars
growth market of biosimilars
Through our biosimilar projects, we are not only developing high-quality medicines for patients but also creating sustainable value for investors.
1-StartSlider_600x1920
Our commitment to a
sustainable development
sustainable development
Our sustainability strategy describes how we intend to strengthen the positive impact of our business activities, minimize negative impacts and effectively mitigate sustainability-related risks.
Latest News
Corporate News
Formycon and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars
July 14, 2026
Corporate News
Formycon reports positive operational Progress and strong Revenue Growth in the First Quarter of 2026
May 28, 2026
Slider_Square_A
Formycon AG –
Commercial Stage
Biosimilars
Commercial Stage
Biosimilars
Slider_Square_A
Formycon AG –
at home in the Growth Market of Biosimilars
at home in the Growth Market of Biosimilars
Slider_Square_A
Formycon AG –
Our Commitment to a sustainable Development
Our Commitment to a sustainable Development
Latest News
Corporate News
Formycon and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars
July 14, 2026
Corporate News
Formycon reports positive operational Progress and strong Revenue Growth in the First Quarter of 2026
May 28, 2026
Key financial figures
Biosimilars
Biosimilar Candidates
Key financial figures
Biosimilars
Biosimilar Candidates
